This paper discusses extracorporeal removal of viral particles and their antigens from the blood as an auxiliary therapy. This hypothesis has not been reported before. In some chronic blood-borne viral infections, the virus remains systemic and persistent for extended periods of time, with adverse effects that weaken the immune system. Blood titers of virus and its toxins are proportional to th...

The synthesis of the title compound, bitamycin, by means of BU4NF is described. This new antiviral drug was found to be one of the most powerful and least toxic substances for antiviral therapy in man. The physical and chemical behavior as well as the antiviral activities and clinical properties of this compound were found to be significantly different from that reported by Schaeffer, et a...

conclusions further studies on the role of hepcidin in pathogenesis of chc are needed to assess the potency of its use in antiviral treatment. results patients with chc had lower hepcidin mrna expression and more frequently iron deposits in hepatocytes than subjects with chb did. in chc group, hepcidin mrna expression was positively correlated with alanine aminotransferase activity and serum ir...

BACKGROUND AND OBJECTIVE Acute retinal necrosis (ARN) may lead to severe visual loss because of its rapid progression and high likelihood of retinal detachment (RD). This study investigates whether combination systemic and intravitreal antiviral therapy is superior to systemic antiviral therapy alone. PATIENTS AND METHODS Single-center, interventional, comparative case series of patients with...

results it was found that the positive hepatitis b surface antigen (hbsag), the high baseline hbv dna level, the positive hepatitis b virus e antigen (hbeag), and an absent or low hepatitis b surface antibody (hbsab) titer prior to starting treatment are the most important viral risk factors. furthermore, rituximab, anthracycline, and different types of tnf-α inhibitors were identified as the h...

the synthesis of the title compound, bitamycin, by means of bu4nf is described. this new antiviral drug was found to be one of the most powerful and least toxic substances for antiviral therapy in man. the physical and chemical behavior as well as the antiviral activities and clinical properties of this compound were found to be significantly different from that reported by schaeffer, et al. al...

Although much advancement has been achieved in the treatment of chronic hepatitis B, antiviral resistance is still a challenging issue. Previous generation antiviral agents have already developed resistance in a number of patients, and it is still being used especially in resource limited countries. Once antiviral resistance occurs, it predisposes to subsequent resistance, resulting in multidru...

Hepatitis C virus (HCV) is an important global health problem with an estimated prevalence of more than 170 million infected individuals worldwide. Currently, the standard antiviral therapy, based on pegylated interferon alpha and ribavirin, can achieve a virological response in only nearly 50% of the patients infected with HCV genotype 1, the most widely distributed globally. During the last y...

BACKGROUND Chronic hepatitis B and C infections represent major risk factors for the development of hepatocellular carcinoma (HCC). Recently, the management of patients with viral hepatitis has dramatically changed. In the present review we discuss the impact of these developments on the prevention of HCC as well as the treatment of patients with HCC. METHODS Studies indexed in Medline betwee...